NMC
NEA Management Company Portfolio holdings
AUM
$1.33B
This Quarter Return
+11.66%
1 Year Return
+85.82%
3 Year Return
+531.37%
5 Year Return
+304.32%
10 Year Return
+4,927.96%
AUM
$1.77B
AUM Growth
+$1.77B
(-3.5%)
Cap. Flow
-$39.3M
Cap. Flow
% of AUM
-2.22%
Top 10 Holdings %
Top 10 Hldgs %
78.21%
Holding
43
New
–
Increased
2
Reduced
2
Closed
1
Top Buys
| 1 |
Marker Therapeutics
MRKR
|
$1.72M |
| 2 |
Oric Pharmaceuticals
ORIC
|
$533K |
Top Sells
| 1 |
OKUR
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
|
$37M |
| 2 |
CVRx
CVRX
|
$4.36M |
| 3 |
MYND
Mynd.ai
MYND
|
$165K |
Sector Composition
| 1 | Healthcare | 85.86% |
| 2 | Technology | 7.19% |
| 3 | Consumer Staples | 6.17% |
| 4 | Communication Services | 0.58% |
| 5 | Industrials | 0.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Arcellx
ACLX
$3.85B
| $287M | 16.21% | 3,745,262 | – | – |
|
|
VRNA
2
Verona Pharma
VRNA
$9.16B
| $259M | 14.64% | 5,584,753 | – | – |
|
|
TEM
3
Tempus AI, Inc. Class A Common Stock
TEM
$13.2B
| $182M | 10.26% | 5,385,979 | – | – |
|
4
Rhythm Pharmaceuticals
RYTM
$6.85B
| $163M | 9.19% | 2,909,956 | – | – |
|
5
NextNav
NN
$2.37B
| $127M | 7.19% | 8,189,156 | – | – |
|
6
Coursera
COUR
$1.88B
| $109M | 6.17% | 12,867,769 | – | – |
|
7
Savara
SVRA
$567M
| $75.1M | 4.24% | 24,471,264 | – | – |
|
|
MBX
8
MBX Biosciences, Inc. Common Stock
MBX
$507M
| $66.6M | 3.76% | 3,614,486 | – | – |
|
9
CRISPR Therapeutics
CRSP
$4.71B
| $62.5M | 3.53% | 1,587,854 | – | – |
|
10
Monte Rosa Therapeutics
GLUE
$296M
| $53.4M | 3.01% | 7,692,298 | – | – |
|
11
Trevi Therapeutics
TRVI
$883M
| $48.8M | 2.76% | 11,370,376 | – | – |
|
12
Korro Bio
KRRO
$217M
| $41.5M | 2.34% | 1,090,793 | – | – |
|
13
Aurinia Pharmaceuticals
AUPH
$1.58B
| $35.6M | 2.01% | 3,969,834 | – | – |
|
|
14
CVRx
CVRX
$205M
| $25.7M | 1.45% | 2,026,083 -344,459 | -15% | -$4.36M |
|
|
ZBIO
15
Zenas BioPharma, Inc. Common Stock
ZBIO
$674M
| $21.4M | 1.21% | 2,613,948 | – | – |
|
16
NeueHealth
NEUE
$59.2M
| $20.2M | 1.14% | 2,726,917 | – | – |
|
17
Gossamer Bio
GOSS
$562M
| $16.4M | 0.92% | 18,093,034 | – | – |
|
18
Celcuity
CELC
$2.17B
| $16.4M | 0.92% | 1,250,001 | – | – |
|
19
Phathom Pharmaceuticals
PHAT
$864M
| $15.9M | 0.9% | 1,960,169 | – | – |
|
20
Champions Oncology
CSBR
$93.8M
| $14.7M | 0.83% | 1,713,720 | – | – |
|
|
21
Oric Pharmaceuticals
ORIC
$994M
| $12.6M | 0.71% | 1,566,081 +66,081 | +4% | +$533K |
|
22
X4 Pharmaceuticals
XFOR
$84.3M
| $11M | 0.62% | 14,986,793 | – | – |
|
23
BuzzFeed
BZFD
$72.6M
| $10.2M | 0.58% | 3,833,473 | – | – |
|
|
RGLS
24
DELISTED
Regulus Therapeutics
RGLS
| $10.2M | 0.58% | 6,467,802 | – | – |
|
25
Geron
GERN
$893M
| $9.83M | 0.55% | 2,776,409 | – | – |
|